Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech

BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC platform technology.

• The companies will collaborate on formulation, optimization, and in vitro testing.

• "We are thrilled to partner with this world-class organization to demonstrate the capabilities of our LNC platform further and potentially provide an opportunity for the oral administration of vaccines or other treatments,' said Jerome Jabbour, CEO & Co-Founder of Matinas.

• Related: Matinas BioPharma Stock Jumps After Meningitis Candidate Data.

• Under the agreement terms, Matinas will receive an upfront access fee to work exclusively with BioNTech and additional research funding from BioNTech. Specific deal terms were not disclosed.

• The parties have also commenced discussions on a license agreement for Matinas' LNC platform technology.

• Price Action: MTNB shares are up 2.97% at $0.80, and BNTX shares are down 0.70% at $169.06 on Monday's last check.

See more from Benzinga

• Europe Holds Second COVID-19 Booster Dose For People Aged Under 80 Years

• FDA Official Says Frequent COVID-19 Booster Shows Not Sustainable: WSJ

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.